201 related articles for article (PubMed ID: 30168534)
21. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma.
Wang M; Wu M; Yang T
EBioMedicine; 2019 Feb; 40():11-12. PubMed ID: 30651221
[No Abstract] [Full Text] [Related]
22. Hepatocellular carcinoma: The beginning of a long journey.
Cascinu S
Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
[No Abstract] [Full Text] [Related]
23. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
24. Joining the dots for better liver cancer treatment.
Chan LK; Ng IO
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):74-75. PubMed ID: 31712772
[No Abstract] [Full Text] [Related]
25. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
26. Hepatocellular carcinoma in the era of immunotherapy.
Sim HW; Knox J
Curr Probl Cancer; 2018; 42(1):40-48. PubMed ID: 29150141
[TBL] [Abstract][Full Text] [Related]
27. From a cancer drug fund to value based pricing of drugs.
Duerden M
BMJ; 2010 Aug; 341():c4388. PubMed ID: 20705656
[No Abstract] [Full Text] [Related]
28. Reply to M. Bouattour et al.
Cainap C; McKee MD; Ricker JL
J Clin Oncol; 2015 Aug; 33(22):2486. PubMed ID: 26033815
[No Abstract] [Full Text] [Related]
29. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
30. Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Chen WC; Chen W; Tseng GC; Lai HC; Shih CM; Hsia TC
Liver Int; 2010 Nov; 30(10):1548-9. PubMed ID: 20345702
[No Abstract] [Full Text] [Related]
31. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
32. Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?
Rizzo A
Expert Opin Investig Drugs; 2022 Apr; 31(4):333-335. PubMed ID: 34176423
[No Abstract] [Full Text] [Related]
33. Novel treatments for hepatocellular cancer.
Kerr SH; Kerr DJ
Cancer Lett; 2009 Dec; 286(1):114-20. PubMed ID: 19664880
[TBL] [Abstract][Full Text] [Related]
34. Trends in the development of MET inhibitors for hepatocellular carcinoma.
Okuma HS; Kondo S
Future Oncol; 2016 May; 12(10):1275-86. PubMed ID: 26984595
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib in advanced hepatocellular carcinoma.
Copur MS
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
[No Abstract] [Full Text] [Related]
36. [Targeted HCC therapies: the door has been opened!].
Rosmorduc O; Fartoux L
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):1-2. PubMed ID: 18341969
[No Abstract] [Full Text] [Related]
37. [Hepatocellular carcinoma].
Yamashita T; Arai K; Kaneko S
Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapies for hepatocellular carcinoma.
Skelton MR; O'Neil B
Clin Adv Hematol Oncol; 2008 Mar; 6(3):209-18. PubMed ID: 18391920
[TBL] [Abstract][Full Text] [Related]
39. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Kelley RK
J Clin Oncol; 2013 Oct; 31(28):3483-6. PubMed ID: 23980088
[No Abstract] [Full Text] [Related]
40. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
